The paper identifies technical challenges,

The gap

Evidence profile

Sourced from the future work and stated research gap and stated challenges of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Myxovirus Resistance Protein A (MxA) in Systemic Lupus Erythematosus: A Review of Recent Advances in Diagnosis and Disease Management (2026) · Global Insights in Medicine and Nursing · doi

  MxA is an important downstream effector of IFN-I pathway and may be useful for SLE diagnosis and treatment. The biomarker is highly expressed in PBMC of SLE patients and in the kidney tissues of LN patients, and may change as the disease activity changes. Depending on the response it could respond to treatment. Clinical applications still require standards of detection, avoidance of interfering factors, popularization on the up-level. In future, speed and standards of diagnosis should be accelerated, detection norms and key values should be made unified, MxA combined with IFN-α, IL-6, etc. might be effective in predicting diagnosis and prognosis; MxA might be a therapeutic target; large-sample multi-center prospective studies could clarify limits and application limits on early diagnosis, prognosis, treatment, and SLE. As standardized detection, multiple markers, large-scale studies continue, MxA will be a biomarker across SLE from early screening and disease monitor to a precise treatment, to further improvement of SLE diagnosis and Treatment at an individual level and quantitative level.

  generalfuture workevidence 5/5
  Keywords: diagnosis treatment detection level biomarker patients disease standards prognosis large limits early important downstream effector
• Novel Biomarkers for Early Detection and Risk Stratification in Chronic Kidney Disease (2026) · KIDNEYS · doi

  There is a need for novel biomarkers that can detect kidney damage earlier and predict disease progression more accurately than traditional tests. There is a need for large-scale validation and global collaboration to address translational barriers and improve patient outcomes. There is a gap in the development of new proteomic and metabolomic techniques that allow multiple biomarkers to be combined into panels, improving the prediction of kidney and cardiovascular outcomes.

  generalstated research gapevidence 5/5
  Keywords: there need novel biomarkers detect kidney damage earlier
• Next-Generation Immunohistochemical and RNA in Situ Hybridization Assays for Renal Neoplasia: Which Biomarkers Are Ready for Prime Time? (2026) · Cancers · doi

  The paper identifies technical challenges, such as the limitations of traditional immunohistochemical evaluation and the need for new biomarkers. It also identifies domain challenges, such as the increasing diversity of renal epithelial neoplasms and the need for accurate diagnosis and classification. The paper mentions the challenge of distinguishing between biomarkers supported for broader or selective clinical implementation and those requiring additional validation.

  generalstated challengesevidence 5/5
  Keywords: paper identifies technical challenges limitations traditional immunohistochemical evaluation

Questions about this gap